SCHEMBL2407901

SCHEMBL2407901

COc1ccc(-n2c(=O)cc(O)c3cccnc32)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.52
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
KAT2B Q92831 1/20 0.48
PDE10A Q9Y233 1/20 0.44
APLNR P35414 1/20 0.44
ALDH1A1 P00352 4/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
PDE4B Q07343 1/20 0.43
G6PD P11413 1/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 1/20 0.43
PSMD14 O00487 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
HSP90AA1 P07900 1/20 0.43
MAPK1 P28482 1/20 0.43
OPRK1 P41145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2409501 0.84 FEN1 (0.57) MAPTKAT2BALDH1A1TSHRPDE4B
SCHEMBL5871817 0.79 MAPT (0.61) MAPTLMNAALDH1A1KDM4EMEN1
SCHEMBL11544557 0.79 MAPT (0.59) PKMMAPTLMNAAPLNRALDH1A1
SCHEMBL25722366 0.76 ALDH1A1 (0.50) PKMMAPTLMNAKAT2BPDE10A
SCHEMBL4185632 0.76 PDE4B (0.48) PDE10APDE4BKMT2A
SCHEMBL2406659 0.75 KMT2A (0.55) MAPTLMNAALDH1A1CYP1A2TSHR
SCHEMBL7278394 0.75 LMNA (0.51) PKMMAPTLMNAKAT2BPDE10A
SCHEMBL30879389 0.75 APLNR (0.45) MAPTLMNAAPLNRALDH1A1CYP1A2
SCHEMBL7281424 0.74 PKM (0.49) PKMMAPTLMNAKAT2BPDE10A
SCHEMBL14096393 0.73 PKM (0.67) PKMMAPTLMNAKAT2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A PKM 1392/4885MAPT 4759/4885LMNA 3363/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A PKM 1459/4885MAPT 4771/4885LMNA 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.